
Table of Contents
Medical AI startup Studio Kiko, developer of an ambient AI scribe that listens to doctor-patient conversations in real time and automatically generates clinical notes, has successfully raised pre-Series A funding. Smilegate Investment, Korea Investment Accelerator, and Strong Ventures participated in the round, though the investment amount remains undisclosed. Studio Kiko officially announced the news on the 6th, positioning its product as a significant entrant into a rapidly growing global category.
What Studio Kiko’s Ambient AI Scribe Does
The company’s service, Neardoc, functions as an ambient AI scribe that listens to conversations between doctors and patients in the examination room in real time, then generates complete clinical notes without any additional input and enters them directly into the electronic medical record system. This positions Neardoc within a category known as clinically specialized ambient AI scribes, one of the fastest-growing segments of the global medical AI market.
A Market Growing Nearly Fivefold
Adoption of this technology is accelerating rapidly, with approximately 70% of all physicians in the United States already using AI charting tools. The ambient AI scribe market overall is projected to expand nearly fivefold, from $6 billion in 2025 to $30 billion by 2033, reflecting the scale of demand driving Studio Kiko’s timing.
Competing Against Global Ambient AI Scribe Leaders
Competition in the global ambient AI scribe market is fierce, with significant enterprise valuations at stake. Industry leader Abridge has been valued at approximately ₩7.4 trillion (roughly $4.8 billion), while second-place Nabla has been valued at approximately ₩4.9 trillion (roughly $3.2 billion). South Korea, by contrast, had virtually no fully developed solutions until now.
Filling a Gap in the Domestic Market
Existing domestic services in South Korea were limited to basic dictation-level functionality or carried the risk of generating factually incorrect information by relying on general-purpose AI. Studio Kiko says it has overcome these limitations with its proprietary medical AI engine, Xynar, calling Neardoc Asia’s first commercialized, globally competitive, fully developed ambient AI scribe.
Rapid Adoption Without Advertising
Without any advertising, Neardoc was adopted by more than 300 clinics and hospitals within just two months of launch, driven solely by word-of-mouth among physicians. This organic growth suggests strong product-market fit for the ambient AI scribe, particularly among practitioners already frustrated with existing documentation tools.
Measurable Results at Adopting Hospitals
Adopting hospitals are already seeing tangible results from the ambient AI scribe. Charting time has been reduced by 70%, and the number of patients seen has increased 1.5-fold. The Net Promoter Score, which measures patient satisfaction, has also risen following adoption.
Where Studio Kiko’s Ambient AI Scribe Is Headed Next
Studio Kiko plans to focus its new investment on recruiting talent and enhancing its service. Going forward, the company intends to expand its ambient AI scribe into clinical decision support systems and a broader “Medical OS,” or medical autonomous operating system. It also aims to pursue a phased entry into non-English-speaking Asian markets by 2027.
Leadership and Investor Confidence
Studio Kiko CEO Kim Se-hoon said the company aims to create examination rooms where doctors can fully focus on their patients and build a future medical infrastructure enabling top-tier care anywhere. Cho Yu-jin, team leader at Smilegate Investment, said Studio Kiko has all the ingredients — a proven founding team, a proprietary AI engine, and the early achievement of securing 300 hospitals without advertising — to lead the Asian ambient AI scribe market.
